We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.
Leoncini, L., Rondoni, M., Arpinati, M., Paolini, S., Candoni, A., Fanin, R., et al. (2007). Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. HAEMATOLOGICA, 92(12), 1721-1722 [10.3324/haematol.11345].
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study
LEONCINI, LORENZO;PIRROTTA, MARIA TERESA;F. LAURIA;
2007-01-01
Abstract
We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1721.full.pdf
accesso aperto
Tipologia:
PDF editoriale
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
195.48 kB
Formato
Adobe PDF
|
195.48 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/393910
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo